Advertisement

Topics

Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500

10:29 EDT 5 Jul 2017 | BioPortfolio Report Blog

Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Pipeline Review, H1 2017, provides an overview of the Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology pipeline landscape.

Acute myelocytic leukemia AML, also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 98, 105, 1, 5, 171, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 16, 14, 31 and 13 molecules, respectively.

Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology.
The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.
The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.
Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology.
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Oncology pipeline depth and focus of Indication therapeutics.
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Original Article: Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500

NEXT ARTICLE

More From BioPortfolio on "Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...